Back to News
Market Impact: 0.3

Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer

Source: Nasdaq

Healthcare & Biotech

Radiopharm Theranostics reported encouraging results from its Phase 1 imaging trial of RAD301 in patients with pancreatic ductal adenocarcinoma. The positive early-stage clinical update supports further development of the oncology radiopharmaceutical candidate, though the article provides no efficacy figures or financial details.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

moderately positive

Sentiment Score

0.45

Ticker Sentiment

RADX0.72

More News